Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate

• Published in: iScience Vol. 26; no. 11; p. 108147
• Main Authors: Uraki, Ryuta, Ito, Mutsumi, Kiso, Maki, Yamayoshi, Seiya, Iwatsuki-Horimoto, Kiyoko, Sakai-Tagawa, Yuko, Imai, Masaki, Koga, Michiko, Yamamoto, Shinya, Adachi, Eisuke, Saito, Makoto, Tsutsumi, Takeya, Otani, Amato, Fukushi, Shuetsu, Watanabe, Shinji, Suzuki, Tadaki, Kikuchi, Tetsuhiro, Yotsuyanagi, Hiroshi, Maeda, Ken, Kawaoka, Yoshihiro
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 17.11.2023; Elsevier BV; Elsevier
• Subjects: Clinical microbiology; Q; Science; Virology; Clinical microbiology; Virology

The emergence and spread of new SARS-CoV-2 variants with mutations in the spike protein, such as the XBB.1.5 and XBB.1.9.1 sublineages, raise concerns about the efficacy of current COVID-19 vaccines and therapeutic monoclonal antibodies (mAbs). In this study, none of the mAbs we tested neutralized X...